Falk Nimmerjahn

This study develops a human immune system mouse model for EBA, demonstrating that PDK1 inhibition reduces skin inflammation and immune cell activation.

This paper evaluates a novel Fc-optimized antibody drug conjugate targeting CD7, showing potent anti-leukemia activity in preclinical T-ALL models.

This study identifies ZEB1 as a key regulator of TAM-mediated T cell trafficking, enhancing CTL recruitment and immunosurveillance in tumors and metastases.